**Borrelia burgdorferi** glycosaminoglycan-binding proteins: a potential target for new therapeutics against Lyme disease

Yi-Pin Lin,1,2,* Lingyun Li,3 Fuming Zhang4 and Robert J. Linhardt4,5,6,*

**Abstract**

The spirochete bacterium *Borrelia burgdorferi sensu lato* is the causative agent of Lyme disease, the most common vector-borne disease in North America and Europe [1]. Three prominent species, *B. burgdorferi*, *B. afzelii* and *B. garinii*, are the causative agents of Lyme disease in Europe, whereas *B. burgdorferi sensu stricto* is the major species causing Lyme disease in North America [2]. Approximately 30,000 new Lyme disease cases are reported in the United States each year (mainly in the northeastern or midwestern United States), justifying the classification of Lyme disease *borreliae* as an 'emerging pathogen' [1]. Following the tick bite, the spirochete establishes infection by colonizing the bite site in the skin, resulting in the erythema migrans skin rash that is characteristic of the early acute phase of infection [1, 3]. If left untreated, Lyme disease *borreliae* is able to spread through the bloodstream to different tissues and organs, including the joints, heart and nervous system, leading to multiple disease manifestations, including arthritis, carditis and neuroborreliosis in the late chronic phase of infection [1].

Unfortunately, no effective prophylactic agents to protect humans from Lyme disease are currently available [1]. Whereas antibiotics are commonly used to treat Lyme disease patients in the early acute and late stages of infection [4], some antibiotic-treated individuals continue to demonstrate joint swelling and longstanding arthritis, known as antibiotic-refractory arthritis [5]. Therefore, there is a critical need to investigate other approaches as complementary methods for limiting disease progression and persistence. Lyme disease *borreliae* requires glycosaminoglycan (GAG)-binding activity to colonize and disseminate to tissues [6, 7]. GAG analogues may thus represent potential therapeutics to block Lyme disease infection. In fact, several kinds of such compounds (e.g. fucoidan, suramin and heparosan) have demonstrated the ability to inhibit the attachment of other pathogens to mammalian cells and reduce infectivity [8–12]. In addition, various GAG-based inhibitors have been examined for their safety in humans and are currently

**INTRODUCTION TO LYME DISEASE**

Lyme disease, which is caused by the spirochete *Borrelia burgdorferi sensu lato* and transmitted by *Ixodes* ticks, is the most common vector-borne disease in North America and Europe [1]. Three prominent species, *B. burgdorferi*, *B. afzelii* and *B. garinii*, are the causative agents of Lyme disease in Europe, whereas *B. burgdorferi sensu stricto* is the major species causing Lyme disease in North America [2]. Approximately 30,000 new Lyme disease cases are reported in the United States each year (mainly in the northeastern or midwestern United States), justifying the classification of Lyme disease *borreliae* as an ‘emerging pathogen’ [1]. Following the tick bite, the spirochete establishes infection by colonizing the bite site in the skin, resulting in the erythema migrans skin rash that is characteristic of the early acute phase of infection [1, 3]. If left untreated, Lyme disease *borreliae* is able to spread through the bloodstream to different tissues and organs, including the joints, heart and nervous system, leading to multiple disease manifestations, including arthritis, carditis and neuroborreliosis in the late chronic phase of infection [1].

Unfortunately, no effective prophylactic agents to protect humans from Lyme disease are currently available [1]. Whereas antibiotics are commonly used to treat Lyme disease patients in the early acute and late stages of infection [4], some antibiotic-treated individuals continue to demonstrate joint swelling and longstanding arthritis, known as antibiotic-refractory arthritis [5]. Therefore, there is a critical need to investigate other approaches as complementary methods for limiting disease progression and persistence. Lyme disease *borreliae* requires glycosaminoglycan (GAG)-binding activity to colonize and disseminate to tissues [6, 7]. GAG analogues may thus represent potential therapeutics to block Lyme disease infection. In fact, several kinds of such compounds (e.g. fucoidan, suramin and heparosan) have demonstrated the ability to inhibit the attachment of other pathogens to mammalian cells and reduce infectivity [8–12]. In addition, various GAG-based inhibitors have been examined for their safety in humans and are currently

**Received 8 September 2017; Accepted 31 October 2017**

**Author affiliations:** 1Division of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, NY, USA; 2Department of Biomedical Science, State University of New York at Albany, Albany, NY, USA; 3Division of Environmental Health Science, Wadsworth Center, New York State Department of Health, Albany, NY, USA; 4Department of Chemical and Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, USA; 5Department of Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, USA; 6Departments of Biology and Biomedical Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, USA.

*Correspondence:* Yi-Pin Lin, Yi-Pin.Lin@health.ny.gov; Robert J. Linhardt, linhar@rpi.edu

**Keywords:** Lyme disease; glycosaminoglycan; proteoglycan; adhesin; heparin; *Borrelia burgdorferi*.

**Abbreviations:** AG, aggrecan; BG, biglycan; C6S, chondroitin-6-sulfate; DC, decorin; DS, dermatan sulfate; ECM, extracellular matrix; GAG, glycosaminoglycan; GOF, gain of function; HS, heparan sulfate; Lmp1M, middle region of Lmp1; LOF, loss of function; NACH, non-anticoagulant heparin; ND, not determined; PG, proteoglycan.
used in patients for different diseases [13], and this could potentially reduce the time required to develop such drugs as treatment for human Lyme disease. In this review, we have summarized the current findings on \textit{B. burgdorferi} GAG-binding proteins and their ability to facilitate Lyme disease infection. We have also discussed the potential for developing GAG analogues as new therapeutic agents for the treatment of Lyme disease \textit{Borreliae} to stop the progression of infection-induced manifestations.

**PROTEOGLYCANS AND GLYCOSMINOGLYCANS, AND THE ABILITY OF LYME DISEASE \textit{BORRELIAE} TO BIND TO THESE LIGANDS**

The capacity of Lyme disease \textit{borreliae} to cause disease manifestations is correlated with its ability to colonize tissues or organs [14]. Tissue colonization is partly attributable to bacterial binding to the extracellular matrix (ECM) on the host cell surface [14]. Proteoglycans (PGs) are ECM molecules composed of a core protein, from which extend long, linear, and negatively charged polysaccharide chains called GAGs [15]. These PGs, including decorin, biglycan, aggrecan, syndecan, glypican and perlecan, are either inserted into the cell membrane or localized to the cell surface ECM (Fig. 1a) [15]. These GAGs are classified based on the structure and composition of their disaccharide repeating units [15]. For example, within the chondroitin sulfate family (indicated by the red dashed lines) of GAGs, there are multiple members with different disaccharide repeating units (Fig. 1b). The most common units are chondroitin-4-sulfate (type-A), dermatan sulfate (type-B) and chondroitin-6-sulfate (type-C) (Fig. 1b) [15]. Heparin, while not found on the cell surface, is structurally similar to other GAGs (Fig. 1b) and has been used as an important model compound for \textit{in vitro} studies examining the GAG-binding activity of Lyme disease \textit{borreliae} and their proteins [16–23].

Lyme disease \textit{borreliae} bind to different PGs, including decorin, biglycan and aggrecan (Fig. 1a) [24–26]. Decorin-deficient mice are more resistant to spirochete colonization in different tissues, suggesting that decorin-mediated spirochete binding promotes tissue colonization during Lyme disease.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{image.png}
\caption{Various proteoglycans (PG) produced on mammalian cell surfaces and the structure of disaccharide units of GAG proved to bind to Lyme disease \textit{borreliae}. (a) Schematic diagram showing the composition of decorin, biglycan, aggrecan, the syndecan family, the glypican family, and perlecan PGs localized on mammalian cell surfaces. Note that there are different types of syndecans and glypicans, and these PGs differ in the numbers and types of GAG chains they carry. The syndecan and glypican depicted in the figure are representative structures. (b) The structure of the major disaccharide units of chondroitin sulfate A (chondroitin-4-sulfate), chondroitin sulfate B (dermatan sulfate), chondroitin sulfate C (chondroitin-6-sulfate), heparin, and heparan sulfate [while the major disaccharide of heparan sulfate primarily contains glucuronic acid (in place of the iduronic acid prominent in heparin) and is non-sulfated, this GAG can contain many minor sulfated disaccharides with sulfo groups occupying all the same sites found within heparin]. All of these GAGs have structural variability (in molecular weight and the positioning of sulfo groups) and are documented to bind to Lyme disease \textit{borreliae}.}
\end{figure}
infection [27]. *B. burgdorferi* binds less efficiently to the vascular endothelial cells in the absence of biglycan, suggesting that the biglycan-binding activity of spirochetes promotes the bacterial attachment to this cell type [25]. *B. burgdorferi* binding to aggrecan results in the degradation of aggrecan and other ECM components, which suggests that the aggrecan-mediated binding may promote the detachment of spirochetes from the initial infection site to disseminate to distal tissues [26, 28].

These PG-mediated binding activities of *B. burgdorferi* are probably associated with the ability of spirochetes to interact specifically with the GAG chains on these PGs. *B. burgdorferi* binds to different GAGs, including chondroitin sulfate, dermatan sulfate and heparan sulfate (Fig. 1b) [17, 29]. This binding activity of GAGs such as heparan sulfate, dermatan sulfate, and chondroitin sulfate mediates spirochete attachment to mammalian cells (e.g. epithelial Vero cells) [17]. Further, the ability of these GAGs to promote spirochete binding to cells correlates positively with the length of these GAG chains [16]. This finding suggests that the charge-charge interactions contribute to GAG-binding by *B. burgdorferi*.

**GAG- AND PG-BINDING OF LYME DISEASE BORRELIAE: DpbA AND DpbB**

Several outer-surface proteins have been shown to confer spirochete binding to GAGs or PGs (see the summary in Table 1). DpbA and DpbB are the first two PG-binding proteins that have been identified as binding to decorin and biglycan [25, 30]. These proteins were later found to bind to the core protein of decorin with higher affinity and the dermatan sulfate of this PG with slightly lower affinity, suggesting that both core protein and dermatan sulfate modulate the decorin-binding activity of DpbA and DpbB [20, 24]. DpbA and DpbB promote spirochete attachment to different mammalian cell types [21, 25, 31, 32] and are required for spirochete colonization during Lyme infection [33–35]. Whereas DpbB is highly conserved, DpbA is polymorphic, with less than 58% amino acid identity between Lyme disease *borreliae* variants [36]. Consistent with this polymorphism, DpbA variants promote different allelic ability for binding to decorin, biglycan, dermatan sulfate and mammalian cells under either static or flow conditions [25, 31, 32]. Similarly, these variants also confer the distinct tissue tropism associated with Lyme infection [6]. The strain to strain variations of the in vitro and in vivo phenotypes promoted by DpbA have been attributed to the decorin- and dermatan sulfate-binding activity of this protein. DpbA mutant proteins that are specifically defective in binding to these ligands are incapable of promoting spirochete attachment to mammalian cells and the colonization of mouse tissues [6, 31, 37].

**BBK32**

The *B. burgdorferi* outer-surface protein BBK32 was initially reported to bind to an ECM protein fibronectin and was later identified to also bind to dermatan sulfate [22, 38]. Inoculating mice with a low dose of a *bbk32*-deficient *B. burgdorferi* results in reduced colonization at the inoculation site (skin) and joints at early stages of infection, indicating the essential role of BBK32 in promoting optimal infectivity [39, 40]. In addition, ectopically producing BBK32 in a non-infectious and non-adherent *B. burgdorferi* (gain-of-function strain) leads to spirochete attachment to mammalian cells in vitro and localization at joints in vivo during short-term intravenous inoculation [7, 22]. Using intra-vital microscopy, this BBK32-producing strain has also been demonstrated to attach to vasculature by promoting transient interaction, including tethering and dragging of spirochetes [41, 42]. A *bbk32*-deficient *B. burgdorferi* displays decreased levels of binding, specifically to joint vasculature, indicating that BBK32 is a vascular adhesin [43].

The dermatan sulfate- and fibronectin-binding activities of BBK32 have been localized at amino acids 45–68 and 158–182, respectively [7]. The gain-of-function *B. burgdorferi* producing BBK32 with internal deletion at amino acids 45–68 (BBK32Δ45–68) or 158–182 (BBK32Δ158–182) is incapable of binding to mammalian cells, but the cell types that each of these strains are unable to bind vary [7]. Compared to the strain producing BBK32Δ158–182, the gain-of-function strain producing BBK32Δ45–68 displays reduced dragging interactions with the vasculature, indicating that BBK32-mediated GAG binding contributes to vascular interaction [43]. In addition, the BBK32Δ45–68 producing strain binds to joints less efficiently than a wild-type BBK32-producing strain during short-term intravenous inoculation [7]. Consistent with this observation, a *bbk32*-deficient *B. burgdorferi* producing BBK32Δ45–68 colonizes mouse joints less than the gain-of-function strain producing wild-type BBK32 [7]. These results indicate that dermatan sulfate binding of BBK32 confers spirochete localization and colonization specifically at joints.

**OspF family proteins**

By inoculating mice with phages producing peptides derived from different *B. burgdorferi* proteins (known as *in vivo* phage display), ErpK, ErpL, ErpG and BB2.10 have been identified as adhesins that promote the phages binding to the joints, bladders and hearts of mice [44]. These proteins are in the OspF protein family, a sub-family of the Erp proteins (OspEF-related proteins) [45–47]. All OspF family proteins bind to heparan sulfate [23]. ErpG promotes spirochete binding to C6 glial cells, but not other cell types [23], and an ErpG mutant that is defective in heparan sulfate-binding activity is incapable of conferring spirochete attachment to C6 glial cells [23]. *B. burgdorferi* mutant strains with transposons inserted in *erpK* display a survival disadvantage in colonizing mouse ears, hearts, joints and inoculation sites [48]. These results suggest that OspF family proteins contribute to mammalian cell attachment and spirochete colonization during infection, likely by their heparan sulfate-binding activity.
<table>
<thead>
<tr>
<th>GAG- or PG-binding protein</th>
<th>Species/strain</th>
<th>PG or GAG ligands</th>
<th>Cell binding</th>
<th>Vascular interaction via i.v. infection</th>
<th>Tissue interaction via i.v. infection</th>
<th>Tissue colonization via s.c. infection</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Static condition</td>
<td>Flow condition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DbpA</td>
<td><em>B. burgdorferi/B31, N40, N40-D10/E9, 297</em></td>
<td>DC1, BG, DS</td>
<td>+ (GOF*)</td>
<td>+ (GOF)</td>
<td>ND††</td>
<td>+ (LOF)</td>
<td>[6, 20, 21, 25, 30–35, 37]</td>
</tr>
<tr>
<td></td>
<td><em>B. garinii/BPr, SBK40</em></td>
<td>DC, BG, DS</td>
<td>+ (GOF, LOF)</td>
<td>+ (GOF)</td>
<td>ND</td>
<td>+ (LOF)</td>
<td>[6, 25, 31, 32]</td>
</tr>
<tr>
<td></td>
<td><em>B. afzelii/VS461, A91</em></td>
<td>DC, BG, DS</td>
<td>+ (GOF, LOF)</td>
<td>+ (GOF)</td>
<td>ND</td>
<td>+ (LOF)</td>
<td>[6, 25, 31, 32]</td>
</tr>
<tr>
<td>DbpB</td>
<td><em>B. burgdorferi/B31, N40, N40-D10/E9</em></td>
<td>DC, BG, DS</td>
<td>+ (GOF)</td>
<td>+ (GOF)</td>
<td>ND</td>
<td>+ (LOF)</td>
<td>[25, 32, 34]</td>
</tr>
<tr>
<td></td>
<td><em>B. garinii/SBK40</em></td>
<td>DC, BG</td>
<td>+ (GOF)</td>
<td>+ (GOF)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td><em>B. afzelii/A91</em></td>
<td>DC, BG</td>
<td>+ (GOF)</td>
<td>+ (GOF)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>BBK32</td>
<td><em>B. burgdorferi/B31</em></td>
<td>DS</td>
<td>+ (GOF, LOF)</td>
<td>+ (GOF, LOF)</td>
<td>+ (GOF, LOF)</td>
<td>+ (GOF)</td>
<td>[7, 22, 39, 40, 42, 43, 71]</td>
</tr>
</tbody>
</table>

**OsF family proteins**

| ErpG (OspG)               | *B. burgdorferi/B31* | HS†† | + (GOF) | ND | ND | ND | ND | [23] |
| ErpK                      | *B. burgdorferi/B31* | HS | ND | ND | ND | ND | ND | [23] |
| ErpL                      | *B. burgdorferi/B31* | HS | ND | ND | ND | ND | ND | [23] |
| ErpY                      | *B. burgdorferi/B31* | HS | ND | ND | ND | ND | ND | [23] |
| OspF                      | *B. burgdorferi/297* | HS | ND | ND | ND | ND | ND | [23] |
| Erp2S                     | *B. burgdorferi/N-40-D10/E9* | HS | ND | ND | ND | ND | ND | [23] |
| Erp27                     | *B. burgdorferi/N-40-D10/E9* | HS | ND | ND | ND | ND | ND | [23] |
| Lmp1                      | *B. burgdorferi/B31* | G6S§§ | + (LOF) | ND | ND | ND | + (LOF) | [49–51] |
| BhHtrA                    | *B. burgdorferi/B31* | AG|| ||| ND | ND | ND | + (LOF) | [26, 28, 56] |

*i.v.*, intravenous.
†s.c., subcutaneous.
‡ DC, decorin.
§ BG, biglycan.
IDS, dermatan sulfate.
¶+, a positive result shown when particular proteins are produced in the respective strain background (gain of function or loss of function strain).
#GOF, gain of function strains. Because genetic manipulation is not available in species other than *B. burgdorferi*, the function tested using gain of function strains was performed in the background of a high-passage and non-adherent *B. burgdorferi* strain, B313, B314 or B31A.
**LOF, loss of function strains. Because genetic manipulation is not available in the species other than *B. burgdorferi*, the function tested using loss of function strains was performed in the background of *B. burgdorferi* strains B31 or 297.
††ND, not determined, which indicates that particular proteins have not been examined for specific activities.
‡‡HS, heparan sulfate.
§§G6S, chondroitin-6-sulfate.
|||AG, aggrecan.
**Lmp1**

In vivo phage display also reveals *B. burgdorferi* outer-surface protein Lmp1 as an adhesin [44]. Consistent with this finding, an *lmp1*-deficient spirochete binds to chondroitin-6-sulfate and mammalian cells at decreased levels compared to the wild-type parental strain [49]. The cell- and chondroitin-6-sulfate-binding activities are specifically promoted by the middle region of Lmp1 (Lmp1M), which houses unique repeating sequences of 54 amino acids and folds to an α-helix rich structure [49–51]. In addition, spirochetes that lack Lmp1 production are non-infectious in mice via subcutaneous needle infection [50]. Producing Lmp1M in the *lmp1*-deficient strain background restores the colonization defects, raising the possibility that the chondroitin-6-sulfate-binding activity of this protein confers infectivity [49].

**BbHtrA**

*B. burgdorferi* BbHtrA belongs to the family of high-temperature-requiring proteases, acting as a protease or chaperone to stabilize proteins and regulate signalling processes [52, 53]. This protein was first identified as an aggrecan-binding protein [26] and was then demonstrated to be capable of digesting *B. burgdorferi* surface proteins, as well as host aggrecan and other ECM molecules, including fibronectin, decorin, and biglycan [28, 54, 55]. The finding that BbHtrA degrades ECM molecules raises the possibility that this protein, by digesting the *B. burgdorferi*-ECM interactions, facilitates spirochete detachment from the initial infection tissues and dissemination during Lyme infection. Consistent with this, *BbHtrA*-deficient *B. burgdorferi* is unable to colonize the inoculation site, heart and bladder during murine infection [56]. However, the protease activity of BbHtrA also targets other adhesion-irrelevant spirochete proteins that are required for bacterial survival [26, 56]. The relevance of the ability of this protein to digest ECM components and contribute to spirochete dissemination still needs to be determined.

As described above, *B. burgdorferi* produces numerous GAG- and PG-binding proteins that are essential for host colonization and tissue dissemination during infection. The production of these proteins at different stages of infection may reflect the requirement for multiple GAG-binding proteins in *B. burgdorferi*. Therefore, developing structurally similar molecules (e.g. GAG analogues) as inhibitors and inoculating these inhibitors during infection to block the spirochete attachment to GAGs or PGs of host cells may represent an effective strategy to treat infection with Lyme disease *borreliae*.

**THE POTENTIAL FOR USING SYNTHETIC OR SEMISYNTHETIC GAGS AS NEW TREATMENTS AGAINST LYME DISEASE**

Numerous pathogens, including Lyme disease *borreliae*, bind to GAG via surface proteins, which promote colonization and dissemination to tissues and organs [57, 58]. Blocking GAG–pathogen interactions has thus been considered to be an efficient mean of eliminating such infections. One strategy to prevent pathogen–GAG interactions is to identify the GAG-binding proteins of pathogens and then design small-molecule analogues to mimic the motif directly contributing to the GAG-binding activity of these proteins. Surfen (bis-2-methyl-4-amino-quinolyl-6-carbamide) was initially developed as an excipient during insulin production. The ability of this small molecule to neutralize the function of heparin motivated further research that identified surfen as an inhibitor for heparan sulfate-mediated cell attachment of herpes simplex virus [59, 60].

The other strategy to block pathogen–GAG interactions is to use GAG analogues, which bind to GAG-binding proteins on the pathogens to prevent their attachment to and colonization of host cells. Several heparin and heparan sulfate-analogues (as known as heparinoids) have been shown to reduce microbial infections, likely due to their ability to block the pathogen–heparan sulfate interaction. The heparinoid ‘fucoidan’, extracted from brown macroalgae, has been demonstrated to decrease infections caused by various viruses, parasites and bacteria [8, 9]. The documented ability of the synthetic heparinoid ‘soramin’ to inhibit viral and parasite infection resulted in the use of this compound as a treatment for African trypanosomiasis and dengue fever [10]. Another heparinoid, ‘heparasan’, derived from the capsule of some pathogenic bacteria, inhibits bacterial attachment to mammalian cells [11, 12]. These findings raise the possibility of developing GAG analogues as a therapeutic agent to treat Lyme disease infection by blocking the GAG-binding protein-mediated spirochete attachment.

GAGs, including heparin, mediate multiple host functions such as anticoagulation, signal transduction of organ development, host inflammatory response and cell migration [61]. Therefore, one of the documented side-effects of GAG-based therapeutic agents is internal bleeding or thrombocytopenia, caused by the potent anticoagulant activity of these agents [62]. However, periodate oxidation has been applied to these heparin-based compounds to cut through the glucuronic acid in the active site causing the anticoagulant ability while retaining the other biological activities of heparin, generating non-anticoagulant heparins [62, 63]. In addition, unfractionated heparin is usually isolated from porcine skin or bovine lung, with an average molecular weight of approximately 14 000 Da. The heterogeneity and high molecular weight of these molecules make their efficient absorption difficult in humans [64]. The recent development of chemoenzymatic synthesis has been utilized to prepare more specific low and ultra-low molecular weight heparins with improved bioavailability and pharmacodynamics [65, 66] A low-molecular-weight non-anticoagulant heparin (NACH) has been synthesized with low toxicity in vivo and enhanced efficacy for inhibiting tumour metastasis [67–70]. Thus, NACH may have the potential to be developed as a therapeutic against Lyme disease-causing bacteria. Testing of the efficacy of this
compound as an anti-\textit{B. burgdorferi} prophylactic agent is currently ongoing in our laboratory. Further, a previous observation that \textit{B. burgdorferi} treated with Dalteparin (a low-molecular-weight heparin) displays a >75\% reduction of vascular interaction compared to untreated spirochetes [42]. This result suggests the possibility of employing GAG analogues as new prophylaxes and treatments for Lyme disease by blocking the haematogenous dissemination and tissue colonization of Lyme disease \textit{borreliae}.

**CONCLUSION AND FUTURE WORK**

GAG-binding activity has been demonstrated to mediate the colonization and dissemination of Lyme disease \textit{borreliae}. Thus, blocking spirochete attachment to host cells may inhibit disease progression and eventually eradicate these bacteria from humans. GAGs and GAG analogues have been examined for their ability to inhibit the attachment of other pathogens to mammalian cells or tissues. Some of these compounds also display a robust capacity for eliminating pathogen infections. These observations suggest the potential use of GAG analogues as therapeutic agents to treat Lyme disease. Several spirochete GAG-binding proteins have been identified as promoting disease manifestations, which may further facilitate the development of drugs acting against Lyme disease by targeting the binding of these proteins to GAGs. In this review, we have discussed and summarized previous findings concerning spirochete proteins mediating the GAG-binding activity of Lyme disease-causing bacteria, as well as the development of GAG analogues as therapeutics. Such information will provide new directions for the use of GAG analogues as treatments for Lyme disease patients to improve the health of people suffering from Lyme infection.

**Funding information**
This work was supported by a New York State Department of Health Wadsworth Center Start-Up grant (to Y. L.), as well as the following grants: NIH R01HL094463 and NIH R21HL136271 (to R. J. L.), and NIH R01 HL125371 (to R. J. L. and F. Z.).

**Acknowledgements**
We thank Rhodaba Ebady (University of Toronto), Anna Boczula (University of Toronto) and Ashley Marcinkiewicz (New York State Department of Health) for critical reading of the manuscript.

**Conflicts of interest**
The authors declare that there are no conflicts of interest.

**References**


---

**Five reasons to publish your next article with a Microbiology Society journal**

1. The Microbiology Society is a not-for-profit organization.
2. We offer fast and rigorous peer review – average time to first decision is 4–6 weeks.
3. Our journals have a global readership with subscriptions held in research institutions around the world.
4. 80% of our authors rate our submission process as ‘excellent’ or ‘very good’.
5. Your article will be published on an interactive journal platform with advanced metrics.

**Find out more and submit your article at microbiologyresearch.org.**